Search hospitals > Alabama > Mobile
University of South Alabama Mitchell Cancer Institute
Claim this profileMobile, Alabama 36688
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Ovarian Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
130 reported clinical trials
13 medical researchers
Summary
University of South Alabama Mitchell Cancer Institute is a medical facility located in Mobile, Alabama. This center is recognized for care of Cancer, Breast Cancer, Ovarian Cancer, Recurrence, Adenocarcinoma and other specialties. University of South Alabama Mitchell Cancer Institute is involved with conducting 130 clinical trials across 253 conditions. There are 13 research doctors associated with this hospital, such as Moh'd Khushman, Jennifer Scalici,, MD, Sachin G. Pai, and Rodney Rocconi.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Moh'd KhushmanWashington University School of Medicine4 years of reported clinical research
Studies Colorectal Cancer
Studies Solid Tumors
7 reported clinical trials
16 drugs studied
Jennifer Scalici,, MDUSA Mitchell Cancer Institute1 year of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
5 reported clinical trials
8 drugs studied
Sachin G. PaiUniversity of South Alabama Mitchell Cancer Institute7 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
4 reported clinical trials
12 drugs studied
Rodney RocconiUniversity of South Alabama Mitchell Cancer Institute9 years of reported clinical research
Studies Ovarian Cancer
Studies Endometrial Cancer
4 reported clinical trials
24 drugs studied
Clinical Trials running at University of South Alabama Mitchell Cancer Institute
Pancreatic Cancer
Ovarian Cancer
Cancer
Endometrial Cancer
Bile Duct Cancer
Non-Small Cell Lung Cancer
Solid Tumors
Breast Cancer
Lung Cancer
Recurrence
Perioperative Chemotherapy
for Pancreatic Cancer
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
Recruiting4 awards Phase 318 criteria
Monitoring Methods
for Pancreatic Cyst
The purpose of this study is to compare the two approaches for monitoring pancreatic cysts. The study doctors want to compare more frequent monitoring vs less frequent monitoring in order to learn which monitoring method leads to better outcome for patients with pancreatic cysts.
Recruiting1 award N/A3 criteria
Palbociclib + Binimetinib
for Pancreatic Cancer
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients with patients with low grade serous ovarian cancer who have certain changes in the tumor DNA. This trial may also help researchers understand if giving the combination of palbociclib and binimetinib can help improve outcomes among patients with low grade serous ovarian cancer who have previously received a MEK inhibitor. For patients with other tumors, with the exception of lung cancer, colon cancer, melanoma and low grade serous ovarian cancers, this trial may help researchers understand if giving the combination of palbociclib and binimetinib can improve the clinical outcome of survival without progression in patients who have certain changes in their tumor's DNA.
Recruiting1 award Phase 210 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of South Alabama Mitchell Cancer Institute?
University of South Alabama Mitchell Cancer Institute is a medical facility located in Mobile, Alabama. This center is recognized for care of Cancer, Breast Cancer, Ovarian Cancer, Recurrence, Adenocarcinoma and other specialties. University of South Alabama Mitchell Cancer Institute is involved with conducting 130 clinical trials across 253 conditions. There are 13 research doctors associated with this hospital, such as Moh'd Khushman, Jennifer Scalici,, MD, Sachin G. Pai, and Rodney Rocconi.